



STATE OF IOWA

TERRY E. BRANSTAD, GOVERNOR
KIM REYNOLDS, LT. GOVERNOR

DEPARTMENT OF HUMAN SERVICES
CHARLES M. PALMER, DIRECTOR

Iowa Medicaid Drug Utilization Review (DUR) Commission Meeting April 6, 2011

**Location: Learning Resource Center
Fairmeadows Conference Room
3550 Mills Civic Parkway
West Des Moines, Iowa**

Time: 9:30 a.m. – 1:30 p.m.

Final Agenda

1. Welcome & Introductions
 - a) Commission Members and Staff
 - b) Approval of the Minutes
2. Iowa Medicaid Enterprise Update(s)
 - a) Psychotropics in Children - Dr. Wadle
3. Prevalence Report Summary
4. Case Studies
5. Public Comment (See Conflict of Interest Disclosure Form)
6. Prior Authorization
 - a) Colchicine (*Colcrys*) - Updated
 - b) Tesamorelin (*Egrifta*) – Initial Review
 - c) Fingolimod (*Gilenya*) – Initial Review
 - d) Topical Immunomodulators – Second Review
 - e) Proton Pump Inhibitors – Second Review
 - f) Selected Brand Name Drugs – Second Review
 - g) Vitamins, Minerals and Multiple Vitamins – Second Review
7. Public Comment (See Conflict of Interest Disclosure Form)
8. Focus Studies/Provider Education Initiatives
 - a) Cholesterol Lowering Medications Post-MI – Follow Up

- b) Serotonin Syndrome Drug Interactions - Updated
 - c) Atypical Antipsychotics and Metabolic Screening – Updated
 - d) Utilization of Drugs on Beers List – Updated
 - e) Antidepressant Use in Children – Updated
 - f) Treatment of Bipolar Depression – Initial Review
 - g) Inhaled Long Acting Beta Agonists in Asthma – Initial Review
9. Miscellaneous
- a) DUR Digest Vol. 23, No. 3
 - b) SMAC Update
 - c) MedWatch
10. Executive Closed Session
- a) Approval of Minutes
 - b) Prevalence Report - Top 100 Providers by Dollar Amount and Script Count
 - c) Member Profiles
11. Adjournment

Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted twice during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on.

www.iadur.org

For more information contact the DUR Project Coordinator, Pam Smith, R.Ph., at info@iadur.org or (515) 974-3131